NCT06444087

Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation: a French Multicentric Prospective Observational Study

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 192 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this non-interventional study is to describe the evolution of Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on the patients' assessment of pain, oozing, and bad smell.

Detailed description

This study is a prospective (primary data), national, descriptive, non-interventional, multicentre study conducted by medical practice and hospital-based dermatologists across different geographical regions in France. This real-world study does not change the physician-patient relationship or patient management or follow-up. Physicians remain free with their prescriptions and patient follow-up procedures. In fact, secukinumab initiation and all treatment decisions will be made according to routine medical care and independently of study participation. Recruited patients will be longitudinally followed-up for the duration of the study, up to 24 months (± 3 months) after secukinumab initiation or secukinumab treatment discontinuation before the end of the 24 months of follow-up (early discontinuation).

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
OTHER	secukinumab	This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.

Timeline

• Start date: 2024-06-17
• Primary completion: 2027-06-30
• Completion: 2027-06-30
• First posted: 2024-06-05
• Last updated: 2026-01-29

Locations

22 sites across 1 country: France